Literature DB >> 17910085

Alzheimer's disease in Down syndrome: neurobiology and risk.

Warren B Zigman1, Ira T Lott.   

Abstract

Down syndrome (DS) is characterized by increased mortality rates, both during early and later stages of life, and age-specific mortality risk remains higher in adults with DS compared with the overall population of people with mental retardation and with typically developing populations. Causes of increased mortality rates early in life are primarily due to the increased incidence of congenital heart disease and leukemia, while causes of higher mortality rates later in life may be due to a number of factors, two of which are an increased risk for Alzheimer's disease (AD) and an apparent tendency toward premature aging. In this article, we describe the increase in lifespan for people with DS that has occurred over the past 100 years, as well as advances in the understanding of the occurrence of AD in adults with DS. Aspects of the neurobiology of AD, including the role of amyloid, oxidative stress, Cu/ZN dismutase (SOD-1), as well as advances in neuroimaging are presented. The function of risk factors in the observed heterogeneity in the expression of AD dementia in adults with DS, as well as the need for sensitive and specific biomarkers of the clinical and pathological progressing of AD in adults with DS is considered. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17910085     DOI: 10.1002/mrdd.20163

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  86 in total

1.  Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade.

Authors:  Matthew G Bartley; Kristin Marquardt; Danielle Kirchhof; Heather M Wilkins; David Patterson; Daniel A Linseman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.

Authors:  Alberto C Costa
Journal:  Nat Rev Neurol       Date:  2012-03-13       Impact factor: 42.937

3.  Language Characteristics of Individuals with Down Syndrome.

Authors:  Gary E Martin; Jessica Klusek; Bruno Estigarribia; Joanne E Roberts
Journal:  Top Lang Disord       Date:  2009-04

4.  Event-related potential index of age-related differences in memory processes in adults with Down syndrome.

Authors:  Alexandra P Key; Elisabeth M Dykens
Journal:  Neurobiol Aging       Date:  2013-08-29       Impact factor: 4.673

5.  Mild cognitive impairment identified in older individuals with Down syndrome by reduced telomere signal numbers and shorter telomeres measured in microns.

Authors:  Edmund C Jenkins; Lingling Ye; Milen Velinov; Sharon J Krinsky-McHale; Warren B Zigman; Nicole Schupf; Wayne P Silverman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-16       Impact factor: 3.568

6.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

7.  Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status.

Authors:  D M Walsh; E Doran; W Silverman; A Tournay; N Movsesyan; I T Lott
Journal:  J Intellect Disabil Res       Date:  2015-05-29

8.  A cross-sectional analysis of executive function in Down syndrome from 2 to 35 years.

Authors:  S J Loveall; F A Conners; A S Tungate; L J Hahn; T D Osso
Journal:  J Intellect Disabil Res       Date:  2017-07-20

Review 9.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

10.  Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.

Authors:  Juliet A Moncaster; Roberto Pineda; Robert D Moir; Suqian Lu; Mark A Burton; Joy G Ghosh; Maria Ericsson; Stephanie J Soscia; Anca Mocofanescu; Rebecca D Folkerth; Richard M Robb; Jer R Kuszak; John I Clark; Rudolph E Tanzi; David G Hunter; Lee E Goldstein
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.